Please assess the completion status of the following clinical trial:

Trial Title: TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients displaying abnormal fasted triglycerides (\> 2 g/L \[2.26 mmol/L\] and less than or equal to 10 g/L \[11.29 mmol/L\]) and/or fasted low density lipoprotein cholesterol (LDL-CHO; \> 1.6 g/L \[4.15 mmol/L\])~* Patients on stable HAART with 2 NRTIs + 1 NNRTI or 1 PI for at least 3 months prior to screening, and with plasma viral load \< 400 copies/mL for at least 6 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Truvada (Type: EXPERIMENTAL): Truvada once daily with continuation of the current NNRTI or PI at randomization
- Maintain Baseline Regimen (Type: ACTIVE_COMPARATOR): Maintain baseline regimen
- Delayed Truvada (Type: EXPERIMENTAL): Truvada once daily with NNRTI or PI (participants from the comparator group who switched to Truvada during Study Phase 2)
- All Truvada (Type: EXPERIMENTAL): Truvada once daily with NNRTI or PI (all participants who received Truvada during the study, i.e., participants in the Truvada and Delayed Truvada groups)

Based on this trial design, predict the completion outcome and termination type (if applicable).